Impact of Goal-Directed Therapy on Delayed Ischemia After Aneurysmal Subarachnoid Hemorrhage: Randomized Controlled

Aida Anetsberger1, Jens Gempt2, Manfred Blobner1

  • 1Department of Anesthesiology (A.A., M.B., R.B., M.H., G.S., S.S., J.S., J.M., M.E., B.J.), Klinikum rechts der Isar, Technical University Munich, Germany.

Stroke
|July 10, 2020
PubMed

Insights

Goal-directed hemodynamic therapy (GDHT) significantly reduced delayed cerebral ischemia (DCI) after subarachnoid hemorrhage. This improved patient functional outcomes, showing GDHT as a superior treatment strategy.

Area of Science:

  • Neurology
  • Critical Care Medicine
  • Neurosurgery

Background:

  • Delayed cerebral ischemia (DCI) is a major cause of poor outcomes following subarachnoid hemorrhage (SAH).
  • Effective strategies to prevent DCI are crucial for improving patient prognosis after SAH.

Purpose of the Study:

  • To evaluate the efficacy of goal-directed hemodynamic therapy (GDHT) compared to standard care in reducing DCI rates.
  • To assess the impact of GDHT on functional outcomes in patients with SAH.

Main Methods:

  • A prospective randomized controlled trial was conducted with adult patients diagnosed with aneurysmal SAH.
  • Patients were randomized to either standard care or GDHT, which involved advanced hemodynamic monitoring and specific treatment algorithms.
  • The primary endpoint was the incidence of DCI, with functional outcomes assessed using the Glasgow Outcome Scale (GOS) at 3 months post-discharge.

Main Results:

  • GDHT significantly reduced the occurrence of DCI compared to standard care (13% vs. 32%, P=0.021).
  • Patients receiving GDHT demonstrated better functional outcomes at 3 months, with a higher proportion achieving GOS 5 (minor or no deficits) (66% vs. 44%, P=0.025).
  • No significant difference in mortality was observed between the GDHT and standard care groups.

Conclusions:

  • GDHT is effective in reducing DCI rates following subarachnoid hemorrhage.
  • GDHT leads to improved functional outcomes for patients recovering from SAH.
  • The study supports the use of GDHT as a beneficial therapeutic approach in managing SAH patients.
Abstract